CORDIS
EU research results

CORDIS

English EN
Accurate cell signatures for the advancement of personalized medicine

Accurate cell signatures for the advancement of personalized medicine

Objective

Patient/individual specific cells, including induced pluripotent stem (iPS) cells will be crucial in defining tomorrow’s medicine owing to their uses in drug discovery, immunotherapy or cell therapy. These clinical applications require the utmost accurate and reliable identity and purity testing, however, the majority of cells stored worldwide fall short of a sufficient level of characterisation. This project aims at validatating and commercializing an innovative method of diagnostic and quality control for human cells. It is based on our unprecedented ability to measure the expression of millions of uncharted RNA biomarkers called TEs, genetic units that contribute over 50% of the genome but that have been completely disregarded until very recently, mainly due to the challenge imposed by their complex analysis. Our new methodology provides a high-density barcode of cellular identity, opening the door for individual-specific cells to broad applications in biotechnology and medicine alike.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Address

Batiment Ce 3316 Station 1
1015 Lausanne

Switzerland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 149 875

Beneficiaries (1)

Sort alphabetically

Sort by EU Contribution

Expand all

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland

EU Contribution

€ 149 875

Project information

Grant agreement ID: 737562

  • Start date

    1 July 2017

  • End date

    31 December 2018

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 149 875

  • EU contribution

    € 149 875

Hosted by:

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland